GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report

Amber Tong

Senior Editor

The spinout of GlaxoSmithKline’s consumer health unit could reportedly take the form of a $54 billion sale to private equity firms.

It would mark a pivot from previous plans to turn that group into its own listed company — one in which current GSK shareholders can continue to own a stake — amid intense pressure from a pair of activist investors calling for a drastic shakeup at the top.

Advent International, CVC Capital Partners, KKR & Co and Permira are among potential suitors currently vetting the business, Bloomberg reported Tuesday, as are Blackstone and Carlyle Group, which have been heavily involved in life sciences deals in recent years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

FDA approves major depressive drug after rejecting it multiple times in past two decades

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence

GSK tan­goes with pri­vate eq­ui­ty play­ers to ex­plore $54B sale of con­sumer unit in­stead of IPO — re­port

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

Stephen Hahn’s liq­uid biop­sy com­pa­ny Har­bin­ger Health rais­es $140M Se­ries B to launch first can­cer tests by 2025

FDA ap­proves ma­jor de­pres­sive drug af­ter re­ject­ing it mul­ti­ple times in past two decades

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

Da­ta Qual­i­ty 2.0: The Fu­ture of Re­al-World Ev­i­dence

GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report

J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win

Federal government shutdown watch: FDA and industry prep for likely closure Oct. 1

Stephen Hahn’s liquid biopsy company Harbinger Health raises $140M Series B to launch first cancer tests by 2025

FDA approves major depressive drug after rejecting it multiple times in past two decades

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

Data Quality 2.0: The Future of Real-World Evidence